FM
TARS icon

Frazier Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Frazier Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,417,157
Closed -$31.9M – 28
2021
Q4 		$31.9M Hold
1,417,157
– – 2.45% 14
2021
Q3 		$30.5M Hold
1,417,157
– – 2.44% 11
2021
Q2 		$41.1M Sell
1,417,157
-500,000
-26% -$15.6M 3.79% 9
2021
Q1 		$61.8M Hold
1,917,157
– – 4.96% 6
2020
Q4 		$79.2M Buy
+1,917,157
New +$54.6M 6.1% 4

Other funds holding TARS

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Frazier Management's TARS Position: Q1 2022 in Review

Frazier Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2022, closing a stake of 1,417,157 shares — an estimated $31.9M sold.

Frazier Management first reported a position in TARS in Q4 2020 and held it in 5 quarters. The position peaked at $79.2M in Q4 2020. 51 funds tracked by Wall St. Rank hold TARS as of Q1 2022.

  • Frazier Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 1,417,157 Tarsus Pharmaceuticals shares in Q1 2022, an estimated $31.9M.
  • Frazier Management first reported a position in Tarsus Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Frazier Management's Tarsus Pharmaceuticals position peaked at $79.2M in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.